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Abstract
Purpose: To outline the current status of and provide insight into possible future research on the breast lesion
excision system (BLES) as a diagnostic and therapeutic device.
Methods: A systematic search of the literature was performed using PubMed, Embase, and the Cochrane databases
to identify relevant studies published between January 2002 and April 2018. Studies were considered eligible for
inclusion if they evaluated the diagnostic or therapeutic accuracy or safety of BLES.
Results: Ultimately, 17 articles were included. The reported underestimation rates of atypical ductal hyperplasia and
ductal carcinoma in situ (DCIS) ranged from 0 to 14.3% and from 0 to 22.2%, respectively. Complete excision rates for
invasive ductal carcinoma and DCIS ranged from 5.3 to 76.3%. Bleeding was the most frequently reported complication
(0–11.8%). Device-related complications may arise, with an empty basket being the most common (0.6–3.6%). Thermal
damage of the specimen, caused by the use of a radiofrequency cutting wire, was reported in eight of the included
studies. Most thermal artifacts were reported as superficial and small (0.1–1.9 mm).
Conclusions: The BLES, an automated, image-guided, single-pass biopsy system for breast lesions using radiofrequency is
designed to excise and retrieve an intact tissue specimen. It is an efficient and safe breast biopsy method with acceptable
complication rates, which may be used as an alternative to vacuum-assisted biopsies. The variable rate of complete
excision raises questions about the possibility to use BLES as a therapeutic device for the excision of small lesions. Further
research should focus on this aspect of BLES.
Keywords: Breast, Biopsy, Vacuum, Breast cancer, Minimally invasive surgical procedures
Key points
 The Breast Lesion Excision System is designed to
excise and retrieve a single intact tissue specimen.
 Reported underestimation rates of atypical ductal
hyperplasia (ADH) and ductal carcinoma in situ
(DCIS) ranged from 0 to 14.3% and from 0 to 22.2%,
respectively.
 Complete excision rates for IDC and DCIS ranged
from 5.3 to 76.3%.
 Complications are infrequent and comparable with
vacuum-assisted biopsy (VAB).
Introduction
Breast cancer is the most frequently diagnosed cancer and
one of the leading causes of cancer death in women world-
wide [1]. The prevalence and incidence of breast cancer
have increased over the last 25 years in most countries. Due
to increased awareness and screening, up to 53% of cancers
are smaller than 2 cm and asymptomatic at detection [2, 3].
Therefore, technologies aimed at achieving minimally inva-
sive complete resection are being investigated.
Recently, the breast lesion excision system (BLES) has
been developed, which is an automated, image-guided,
single-pass biopsy system using radiofrequency (RF). This
device is designed to extract entire breast lesions, keeping
the tissue architecture intact. The device consists of a
probe that can be inserted through a small skin incision of
6–8mm, with a sharp blade at the distal end to access the
target lesion. Just behind the blade, capture wire electrodes
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are positioned that, once activated, are pushed forward by a
motor in the device handle. In approximately 8 s the device
deploys the RF cutting mechanism, enclosing the target
lesion. To keep the biopsy cavity clear of fluid, which is
essential for RF cutting, vacuum ports are located at the
distal end of the probe. The capture snare enclosing the
specimen can be retracted after the procedure, and a
marker clip can be placed in the biopsy cavity through the
biopsy canal. Figures 1 and 2 show the BLES probe and an
obtained specimen, respectively.
As opposed to other breast biopsy devices, the aim of
BLES is to excise and retrieve an intact breast tissue speci-
men, rather than to obtain fragmented samples [4–7],
which may not only facilitate easier diagnosis but also
might allow for minimally invasive resections.
In this systematic review, we aim to determine the current
status of BLES as a potential diagnostic and therapeutic de-
vice in patients with small suspicious or proven (pre-)malig-
nant breast lesions, and its related complications.
Methods
Search strategy
A search of the literature was performed in order to identify
all articles that examined the diagnostic accuracy, thera-
peutic efficiency, related complications, and/or thermal dam-
age of BLES in patients with suspicious breast lesions. We
searched for articles in PubMed, Embase, and the Cochrane
database to identify English language, peer-reviewed articles
published between January 1, 2002 and April 24, 2018. The
search terms included: breast, percutaneous, intact, speci-
men, sample, biopsy, breast lesion, excision and radiofre-
quency, in various combinations. A full list of all performed
searches is given in Table 5 in the Appendix. Furthermore,
the reference lists of all included articles were manually
searched for relevant references.
Study selection
The search in PubMed and Embase generated 531 and 261
articles, respectively. The Cochrane Library was manually
searched, yielding no relevant articles. Duplicate articles
were manually filtered using the bibliographic EndNote
database, version X8 (Thomas Reuters, New York City, NY,
USA), and 537 potentially relevant articles remained.
Titles and abstracts of the remaining articles were evalu-
ated by two authors (WS and BL). Articles were included
only if they met all of the following criteria: (I) BLES or a
prototype was used as a diagnostic or therapeutic device; (II)
a minimum sample size of 10 patients with suspicious lesions
referred for breast biopsy was included; (III) stereotactic or
ultrasound guidance was used; (IV) the BLES procedure was
followed by open surgery in malignant cases, or clinical
follow-up of at least 1 year if surgery was not indicated.
Data extraction, statistics, and quality assessment
The following characteristics were, if available, collected:
first author, publication year, country, study design,
study period, number of patients, mean age, number of
lesions, type of lesions, lesion size, guidance modality,
Fig. 1 BLES probe
Fig. 2 Specimen obtained with the BLES probe
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used needle size, procedural success rate, histological
data, underestimation rates, complete excision rate, fre-
quency and type of complications, thermal artifacts, and
procedural problems. There was no agreement between
the papers about the definition of complete excision.
Therefore, these definitions were also collected. Results
are presented as aggregated data from individual studies.
Underestimation rates for invasive and in situ malignant
disease associated with the detection of atypical ductal
hyperplasia (ADH) and ductal carcinoma in situ (DCIS) in
the biopsy specimens were used to determine the diagnostic
accuracy of the BLES. “ADH underestimation” was defined
as the percentage of ADH lesions on BLES specimen
upgraded to DCIS or invasive cancer at subsequent excision.
DCIS underestimation was defined as the percentage of
DCIS lesions on BLES biopsy upgraded to invasive cancer
in the surgical specimen. Complete excision rate was
defined as the fraction of BLES excisions with ADH, DCIS,
or invasive cancer that were negative at subsequent surgical
excision (i.e., no residual lesion was found).
The quality of the included studies was evaluated by the
same two independent observers using the Quality Assess-
ment of Diagnostic Accuracy Studies 2 (QUADAS-2) scor-
ing system [8]. This checklist comprises four domains:
patient selection, index test, reference standard, and flow
and timing. Not all signaling questions were relevant to as-
sess the study quality for the present review. Two signaling
questions were added to the QUADAS-2 scoring system: at
the index test domain, the signaling question: “Physicians
who performed the index test had appropriate training or
the first patients were excluded to account for a learning
curve” and at the reference standard domain: “Were patients
who did not receive the reference standard specified?”
Table 6 in the Appendix shows how the QUADAS-2 score
was adapted for this review. Inequalities in scoring by the
observers were subsequently resolved by consensus.
Meta-analysis was not performed due to heterogeneity
across studies regarding patient selection, definition of suc-
cess criteria, and presence or absence of surgical verification
of results.
Results
Studies
Five hundred thirty-seven potential relevant articles
remained after the search. Five hundred eighteen articles
were excluded because they did not use the BLES device
or a prototype. We identified 19 full-text versions of
studies that used the BLES as a diagnostic or therapeutic
device and that fulfilled all the inclusion criteria [4–7,
9–23]. Figure 3 shows the results of the study search
and identification of eligible studies. We did not retrieve
any additional items after reference screening. The study
by Fine et al. [19] was excluded because although a com-
parable device was used, it was not a prototype of BLES.
Citgez et al. [18] published their findings as an abstract
only and was therefore excluded.
The characteristics of the 17 included studies are shown
in Table 1. All studies were observational: 10 studies en-
rolled participants prospectively while 7 studies were
retrospective. In all of these studies, included patients had
known mammographic abnormalities (masses or suspi-
cious calcifications) with a mean lesion size on imaging
ranging from 5.7 mm to 12.7mm (reported range, 1 mm
− 76mm). Mean age ranged from 50.5 years to 61.8 years
(reported range, 21 years–93 years). The number of lesions
ranged from 19 to 1170. Ten studies used stereotactic
guidance during the BLES procedure [4, 6, 7, 9, 11, 13, 15,
16, 20, 22]. Six studies used stereotactic or ultrasound
guidance [5, 10, 12, 14, 21, 23]; only Graham [17]
performed all BLES procedures with ultrasound guidance.
Overall, 4373 BLES biopsies were performed in 17
studies. The procedure was technically successful in
4320 procedures, with success rates varying between
84% and 100%. Eight studies were performed for diag-
nostic purposes only [4, 6, 7, 9, 11, 13, 15, 17]. In two
studies, one or more biopsies were performed to remove
benign lesions for which histology was already known
[21, 23]. One study aimed at a complete, tumor-free
margin excision of small solid carcinomas [22].
Quality assessment
The results of bias risk and applicability according to the
QUADAS-2 evaluation are summarized in Fig. 4. In five
studies, the risk of bias in patient selection was considered
uncertain due to unreported details [5, 11–14]. The study
of Scaperrotta et al. [16] was considered to present a high
risk of bias in patient selection since patients were not con-
secutively enrolled. The decision to use the BLES was en-
tirely based on the radiologist’s assessment. Presence of bias
risk of the index test was uncertain in 11 studies [6, 7, 9, 12,
13, 15–17, 20–22] and high in two studies [10, 23]. The risk
of bias in the “reference standard” domain was generally
scored low. Only the study by Al-Harethee et al. [7] had an
unclear bias risk because there was no information available
about the used reference standard. Admittedly, this was be-
yond the scope of their study. The risk of bias in the flow
and timing was generally scored as high, because not all pa-
tients with a high-risk lesion (HRL) or malignancy based on
the BLES received surgical excision. Only five studies [15,
20–23] were scored with a low risk of this bias and one [7]
with an unclear risk of bias. All studies were deemed ap-
plicable to the research question. In short, no studies were
excluded based on the quality assessment.
Diagnostic accuracy
BLES was, in most studies, used as a diagnostic tool for
breast abnormalities for which histopathology was not yet
available. Diagnostic accuracy was usually reported as the
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underestimation rates of more aggressive disease in lesions
diagnosed as ADH and/or DCIS by BLES. The ADH and
DCIS underestimation rates ranged from 0 to 14.3% and
from 0 to 22.2%, respectively. In addition, the diagnosis
was upgraded by subsequent BLES excision after ADH,
DCIS, or intraductal papilloma was found on core needle
biopsy (CNB) or fine needle aspiration (FNA) cytology in
2.7%, 0.9%, and 19.7% of cases, respectively [21, 23].
Results of all individual studies are shown in Table 2.
Therapeutic accuracy
Only two studies have investigated the ability to use BLES as
a therapeutic device for removal of lesions for which histo-
logical results were already obtained by other means [21,
23]. An additional three studies assessed the therapeutic
value of the system without prior knowledge of histology
[16, 20, 22], and several studies reported the complete exci-
sion rate of biopsied lesions, even though they did not aim
to excise the entire lesion [4, 5, 9–14]. See Table 3.
The median of all reported DCIS complete excision
rates was 50% (range, 0.9–80%) [4, 5, 9–12, 14, 16, 20,
22, 23]. For complete excision rates of ADH, studies
reported a median of 60% (range, 22.2–83.3%) [4, 10, 12,
13, 20, 23]. For complete excision rates of invasive ductal
carcinoma (IDC), the median was 43% (range, 0–62.5%)
[5, 10, 12–14, 16, 20, 22, 23].
Complications and procedural problems
Studies reported various complications associated with the
use of BLES (Table 4), although complications were infre-
quent and usually mild. The most common complications
were bleeding (0–11.8%), hematoma (0–8.8%), infection
(0–5.3%), wound leakage (5.3%), wound healing problems
(0.9–5.2%), and skin burn (0–1.5%) [4, 5, 7, 9–14, 17,
20–23]. In addition to patient-related complications, device-
and procedure-related problems were also reported: wire
break (0.6–1%), basket failed to deploy (0.7–2%), incorrect
guidance (0.9–1.2%), and an empty basket after the proced-
ure (0.6–3.6%) [7, 9, 10, 15, 16, 21, 22]. In the case of
Fig. 3 Flowchart of systematic review
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device-related complications that lead to an unsuccessful
procedure, the use of a second probe was necessary to
complete the procedure.
Thermal damage to the specimen is regularly present due
to the use of the RF-based cutting wire and reported by sev-
eral studies that evaluated the BLES. However, the reported
thermal artifacts were mostly superficial and small. The af-
fected tissue thickness ranged overall from 0.1mm to 1.9
mm [4, 5, 9–12, 14, 15] and was more extensive toward the
pole of the ellipsoid specimen (0.7–1.9mm) than centrally
(0.1–1mm).
Discussion
This systematic review reports on 17 studies on the diag-
nostic and therapeutic accuracy, and complications of
BLES in patients with suspicious breast lesions. A (pooled)
meta-analysis was not performed because of heterogeneity
in study design and included patient populations. Overall,
the procedural success rates are high. Despite the fact that
most studies did not aim to remove lesions entirely,
complete excision occurs regularly, depending on the type
of lesion. Finally, complications are infrequent and usually
mild. Although technical failures might occur due to spe-
cific properties of the BLES, they are infrequent. Although
the device is only approved for diagnostic purposes it cer-
tainly has the potential to be used as a therapeutic device.
The overall study quality of all included studies is
reasonably high according to the QUADAS-2 score.
According to the instructions for use, the QUADAS-2 tool
was tailored for this systematic review, which means that
some signaling questions were added or omitted, as pro-
vided in Table 6 in the Appendix. The signaling question
“Physicians who performed the index test had appropriate
training or the first patients were excluded for the learning
curve?” was added because the likely present learning curve
may have an influence on other variables, such as success
rate, complications, and technical failure. Also, the letter of
Michalopoulos et al. describes that it has been estimated
that for dedicated breast radiologists approximately four
procedures and for those without previous VAB experience
nine procedures are required to gain experience with the
BLES technique [24]. The signaling question “Were patients
who did not receive the reference standard specified?” was
added because surgical excision is mandatory for patients
with a malignant or HRL in the index test. Underestimation
rates of biopsies containing ADH and DCIS are commonly
Fig. 4 QUADAS-2 graph demonstrates the risk of bias and the applicability of assessment results
Table 2 Summary of underestimation rates of BLES in literature
First author ADH underestimation
rate n/N (%)
DCIS
underestimation
rate n/N (%)
Sie et al. (4) 3/32 (9.4) 6/115 (5.2)
Killebrew et al. (9) NA 1/31 (3.2)
Allen et al. (5) NA NA
Seror et al. (10) 0/4 (0) 6/27 (22.2)
Diepstraten et al. (11) NA 0/3 (0)
Whitworth et al. (6) 3/32 (9.4)a NA
Razek et al. (12) 0/14 (0) 0/8 (0)
Medjhoul et al. (13) 0/4 (0)b 1/9 (11.1)
Al-Harethee et al. (7) NA NA
Allen et al. (14) 0/6 (0) 0/11 (0)
Al-Harethee et al. (15) NA NA
Scaperrotta et al. (16) NA 5/32 (15.6)
Graham (17) 1/38 (2.6)b 0/8 (0)
Milos et al. (20) 2/14 (14.3)b 0/10 (0)
Sklair-Levy et al. (21) NA NA
Papapanagiotou et al. (22) NA 0/5 (0)
Niinikoski et al. (23) NA NA
ADH atypical ductal hyperplasia; DCIS ductal carcinoma in situ; n number of
DCIS/IC reference (initially ADH) or number of IC reference (initially DCIS); N
total number of initially ADH or DCIS; NA not available
a23/32 based on open surgical excision, 6/32 based on image follow-up
bHigh-risk lesion underestimation
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used to determine the accuracy of percutaneous biopsy
techniques [25, 26]. Multiple studies focused on ADH or
DCIS underestimation rates of VAB and of CNB with vary-
ing needle sizes. In a systematic review of VAB, Yu et al.
[27] reported a pooled ADH and DCIS underestimation of
20.9% (95% CI 17.7–24.5%) and 11.2% (95% CI 9.8–
12.8%), respectively. Reported underestimation rates for
CNB are generally higher: 44.2% (95% CI 36.0–52.5%) and
22.8% (95% CI 19.0–26.5%), respectively [28]. In the
current review of BLES, ADH and DCIS underestimation
rates are therefore in the same order of magnitude as those
reported for VAB. The en bloc resection obtained with
BLES preserves lesion architecture, which may make subse-
quent histopathological classification easier, facilitating dis-
crimination between atypical and (pre-)malignant lesions.
Furthermore, the possibility to examine the margins of the
lesion allows determination of the excision completeness,
which is crucial for high-risk or (pre-)malignant lesions [29].
However, in normal clinical situations, the BLES will not be
the first choice biopsy device, because it is more invasive,
expensive, and requires adequate training.
The varying rates of complete excision suggest that future
research should focus on the characteristics of lesions for
which BLES can be used for therapeutic resection. It should
be noted that complete excision rates of clusters of suspi-
cious microcalcifications under stereotactic guidance are
low. The cluster size of microcalcifications on mammog-
raphy is anyhow poorly correlated with pathological tumor
size in both DCIS and invasive disease [30]. Therefore, it is
highly recommended to focus future research on lesions
that are clearly visible on mammography or US. It would
be appropriate to modify the needles to make them appro-
priate for MRI-guided biopsy (ferromagnetic-material-free)
so that the lesion size could be measured more precisely
and needle size selection could be adjusted accordingly. It
is important to realize that the basket should be large
enough to capture the entire lesion when the intended use
is therapeutic. An upgraded BLES needle with a diameter
of 30mm is under development. This may further reduce
underestimation rates and expand therapeutic possibilities.
Although most studies recorded the presence of RF coagu-
lation artifacts, these artifacts are most prominent around
the pole of the ellipsoid specimen. A possible explanation is
that the precursor electrode is situated at the distal end of
the probe and tissue is more exposed to this part. Some
studies note that pathologists may have difficulties with in-
terpretation and assessment of edges and margins of lesions
obtained with BLES because of these RF artifacts. However,
this problem seems to wane when the pathologist gains
more experience with BLES samples [9–11, 13, 14]. In fact,
most breast pathologists are used to coagulation artifacts at
the edges of breast specimens as breast surgeons commonly
work with a diathermic knife. Nevertheless, there are some
options to minimize the effect of RF artifacts. First, placing
local anesthetic fluid effectively around the entire lesion,
because dry tissue burns easier. Second, aiming to get the
lesion in the middle of the resection specimen, rather than
at the distal pole, will reduce the effect of thermal damage to
the lesion. Using a larger wand should increase the distance
between the RF artifact and the lesion.
The most frequently reported device-related failure was
an empty basket. The cause of this failure is unknown but
thought to be associated with the presence of excessive
(anesthetic) fluid which blocks the RF cutting mechanism
or the presence of very fatty breast tissue which melts dur-
ing the procedure [9, 15, 31]. Unfortunately, in case of an
empty cage after biopsy, no salvage technique is available
other than marker placement followed by surgical exci-
sion, or when the lesion is still visible, an attempt using
VAB. In case of a basket deployment failure, a second
disposable is necessary, with associated costs, because the
system uses single-shot only needles. Adjusting the nee-
dles for re-use in the same patient could be a solution.
In conclusion, BLES is a diagnostic device with a diagnos-
tic accuracy at least as good as VAB, as expressed by ADH
and DCIS underestimation rates. The technique is safe for
use. Disadvantages of BLES are the reported device-specific
problems and the fact that only one attempt of lesion re-
moval per needle is possible. Advantages include preserva-
tion of lesion architecture, and the possibility to assess lesion
margins. Although there is a small risk of thermal damage to
the biopsy specimen that might hinder pathological evalu-
ation, this appears limited. BLES therefore offers a viable al-
ternative to VAB. Based upon the balance between
advantages and disadvantages, BLES seems most suited for
the complete excision of small breast lesions for which a de-
finitive diagnosis is required (e.g., papillomas). Because BLES
is minimally invasive and permits margin evaluation, the
value of this device may be mainly in the therapeutic field,
future research should therefore focus on this. A “treat and
resect” study design, in which a BLES excision is immediately
followed by a surgical procedure of the biopsy cavity, seems
to be most feasible for the evaluation of the potential of the
technique for treatment of small cancers. This may depend
on the availability of larger basket sizes. It is also important
to assess whether it is possible to predict successful tumor
extraction based upon patient and tumor characteristics, as
adequate patient selection seems mandatory. If such studies
are successful, then follow-up studies should be performed
in large-scale multi-center settings to evaluate the resection
of small invasive carcinomas under local anesthesia only with
BLES, followed by additional surgery only if resection mar-
gins are positive. Afterward, these patients must be followed
for a long period to analyze possible effects on local recur-
rence and disease-free survival. Also, the improvement, if
any, in quality of life should be evaluated. Finally, a
cost-effectiveness analysis from a healthcare perspective is
necessary to assess the impact on healthcare costs.
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Appendix
Table 6 Adapted QUADAS-2 score form
Signaling question Signaling question Risk of bias Concerns about applicability
Domain 1: Patient selection
Was a consecutive or random sample
of patients enrolled?
Did the study avoid inappropriate
exclusions?
Could the selection of patients
have introduced bias?
Are there concerns that the
included patients and setting
do not match the review
question?
Yes: If all consecutive or random
samples of subjects were enrolled.
No: If subjects were nonrandomly
selected.
Unclear: If sampling method was
unclear.
Yes: If there were no inappropriate
exclusion criteria or patients were
excluded with appropriate
arguments.
No: If subjects were excluded based
on inappropriate criteria or with
inappropriate arguments.
Unclear: If selection criteria were
unclear
Low risk: If all signaling questions
answered ‘yes’.
High risk: If ‘no’ was reported for
at least one signaling question, or
if ‘unclear was reported for more
than one signaling question.
Unclear risk: If ‘unclear’ was
reported for one signaling
question.
Low concern: If selected
subjects matched the review
question and inappropriate
exclusions were avoided.
High concern: If selected
subjects differed from those in
the review question.
Unclear concern: If there was
insufficient information on
included subjects and setting.
Domain 2: Index test
Were the index test results interpreted
without knowledge of the results of
the reference standard?
Physicians who performed the index
test had appropriate training or the
first patients were excluded for the
learning curve.
Could the conduct or
interpretation of the index test
have introduced bias?
Are there concerns that the
index test, its conduct, or
interpretation differ from the
review question?
Yes: If the index test results were
interpreted without knowledge of the
histopathological analysis of surgical
specimen or when surgical biopsy only
was offered based on index test
results.
No: If the index test results were
interpreted with knowledge of the
histopathological analysis of surgical
specimen.
Unclear: If it was unclear whether
index test results were interpreted
independently of the histopathological
analysis of surgical specimen.
Yes: If an appropriate training for the
physicians was defined or the first
patients were excluded for the
learning curve.
No: If physicians had no appropriate
training or no patients were excluded
for the learning curve.
Unclear: If it was unclear whether the
physicians had an appropriate
training or patients were excluded for
the learning curve.
Low risk: If all signaling questions
answered ‘yes’.
High risk: If ‘no’ was reported for
at least one signaling question, or
if ‘unclear was reported for more
than one signaling question.
Unclear risk: If ‘unclear’ was
reported for one signaling
question.
Low concern: If the index test
was performed as described in
the review question.
High concern: If the index test
differed from those specified in
the review question.
Unclear concern: If there was
insufficient information
available
Domain 3: Reference standard
Is the reference standard likely to
correctly classify the target condition?
Were patients who did not receive
the reference standard specified?
Could the reference standard, its
conduct, or its interpretation have
introduced bias?
Are there concerns that the
target condition as defined by
the reference standard does
not match the review question?
Table 5 Full list of performed searches
Set Search statement for PubMed and Embasea
#1 Breast lesion excision[tiab]
#2 Breast [tiab] AND Percutaneous excision[tiab]
#3 Breast [tiab] AND Percutaneous biops*[tiab]
#4 Breast [tiab] AND Intact[tiab] AND (Sample*[tiab] OR
Specimen*[tiab])
#5 Percutaneous[tiab] AND Biops*[tiab] AND Breast lesion*[tiab]
#6 Biops*[tiab] AND Breast lesion*[tiab] AND Radiofrequency[tiab]
#7 #1 OR #2 OR #3 OR #4 OR #5 OR #6
aLimited to English language studies in human females, from January 1, 2002
to April 24, 2018
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Abbreviations
ADH: Atypical ductal hyperplasia; BLES: Breast lesion excision system; CNB: Core
needle biopsy; DCIS: Ductal carcinoma in situ; FNA: Fine needle aspiration;
HRL: High-risk lesion; IDC: Invasive ductal carcinoma; LCIS: Lobular carcinoma in
situ; QUADAS-2: Quality Assessment of Diagnostic Accuracy Studies 2;
RF: Radiofrequency; VAB: Vacuum-assisted biopsy
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Signaling question Signaling question Risk of bias Concerns about applicability
Yes: All patients received
histopathological analysis of surgical
specimen.
No: Some or all patients received any
other reference standard or no
reference standard.
Unclear: Reference standard is not
stated.
Yes: If the reference standard was
recommended for all malignant
lesions and High Risk lesions, but was
refrained with appropriate arguments.
No: If the reference standard was not
offered or without appropriate
arguments.
Unclear: Exclusions were not stated.
Low risk: If all signaling questions
answered ‘yes’.
High risk: If ‘no’ was reported for
at least one signaling question, or
if ‘unclear was reported for more
than one signaling question.
Unclear risk: If ‘unclear’ was
reported for one signaling
question.
Low concern: If pathological
analysis of surgical specimen or
mammographic follow-up was
used.
High concern: If pathological
analysis of surgical specimen or
mammographic follow-up was
not used.
Unclear concern: If insufficient
information was provided in
the report.
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answered „yes.
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reported for one signaling
question.
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